Sacubitril / Valsartan Oral Tablet
Sponsors
Oslo University Hospital, RenJi Hospital, Clinision, Shenzhen Second People's Hospital, Montreal Heart Institute
Conditions
Connective Tissue DiseasesHeart FailureHeart Failure NYHA Class IIHeart Failure NYHA Class IVHeart Failure, SystolicHemodialysis ComplicationMyocardial InjuryPeritoneal Dialysis Complication
Phase 4
Pharmacodynamic Effects of Sacubitril/Valsartan on Natriuretic Peptides, Angiotensin and Neprilysin
NCT03553303
Start: 2018-10-16End: 2022-05-31Target: 40Updated: 2019-08-29
Effect of Sacubitril/Valsartan on Reduced Right Ventricular Ejection Fraction in Patients With CTD
NCT04197050
Start: 2020-02-20End: 2022-11-30Target: 60Updated: 2020-01-07
The Effect of Sacubitril/Valsartan on Cardiovascular Events in Dialysis Patients and Efficacy Prediction of Baseline LVEF Value
NCT04572724
Start: 2020-07-06End: 2023-06-30Target: 120Updated: 2020-10-08
Sacubitril/Valsartan Versus Valsartan in Heart Failure
CompletedNCT05881720
Start: 2022-01-01End: 2023-06-19Updated: 2023-06-27
Sacubitril-valsartan in Patients With Heart Failure With Reduced Ejection Fraction From Rural Tanzania
Not yet recruitingNCT06704633
Start: 2026-01-05End: 2028-04-30Target: 238Updated: 2025-08-28
Unknown Phase
Impact of Sacubitril/Valsartan on Quality of Life and Mortality of CKD vs Non-CKD in Heart Failure Patients
CompletedNCT04218435
Start: 2019-01-01End: 2020-12-30Updated: 2021-02-01
ARNI Versus plAcebo in Patients With Congenital sYStemic Right Ventricle Heart Failure
TerminatedNCT05117736
Start: 2022-03-15End: 2023-03-12Updated: 2024-03-13